SGS successfully implements Oracle Argus solution for drug safety and regulatory compliance
Argus improves the quality and timeliness of safety case processing and reporting, and reduces operational risks for both clinical trial and post-marketed pharmacovigilance data.
SGS has successfully implemented the market leading Oracle Argus database in response to changing pharmacovigilance requirements for processing solicited and unsolicited adverse events (AEs).
Oracle’s Argus Safety is a comprehensive safety database designed specifically to address the complex drug safety and pharmacovigilance requirements of the life sciences industries. The system’s advanced database helps to ensure global regulatory compliance, aid faster and more informed safety decisions, and integrates safety and risk management functions.
Argus provides retrospective and real-time analytics for workflow state, case lock, and expedited report submission compliance, to improve the quality and timeliness of safety case processing and reporting. It also reduces operational risks for both clinical trial and post-marketed pharmacovigilance data.
The multi-tenancy feature in Argus Safety allows multiple SGS clients to reside as separate and unique tenants in a single database with their data completely segregated and restricted to authorized users. This feature also enables SGS to achieve standard configurations, such as code lists, workflow steps, and new user setup across clients, or to have different configurations for specific clients. Additionally, SGS users with greater access can view their work across multiple clients and make more informed decisions.
“We can now use a single database for many clients, which reduces the amount of hardware and resources needed for pharmacovigilance implementation,” commented Rafaël Smets, head of Medical Affairs for SGS. He added “We undertook a careful evaluation of all available systems on the market before selecting Oracle’s flagship safety system. Argus Safety is trusted throughout the life sciences sector for its functionality, reliability, compliance, and ease of use, while ongoing enhancements will meet both regulatory and the industry’s evolving needs”.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance